PSMA PET in imaging prostate cancer
I Tsechelidis, A Vrachimis - Frontiers in oncology, 2022 - frontiersin.org
After prostate malignancy diagnosis, precise determination of disease extent are
fundamental steps for tailored made therapy. The earlier the diagnosis of the burden of the …
fundamental steps for tailored made therapy. The earlier the diagnosis of the burden of the …
French AFU Cancer Committee Guidelines-Update 2022-2024: prostate cancer-Diagnosis and management of localised disease
G Ploussard, G Fiard, E Barret, L Brureau… - Progrès en Urologie, 2022 - Elsevier
Objective The objective of the French Urology Association Cancer Committee is to propose
an update of the recommendations for the diagnosis and management of prostate cancer …
an update of the recommendations for the diagnosis and management of prostate cancer …
68Ga-PSMA-11 PET/CT versus 68Ga-PSMA-11 PET/MRI for the detection of biochemically recurrent prostate cancer: a systematic review and meta-analysis
R Huang, Y Li, H Wu, B Liu, X Zhang, Z Zhang - Frontiers in Oncology, 2023 - frontiersin.org
Purpose Our aim was to conduct a meta-analysis and systematic review in order to compare
the diagnostic efficacy of 68Ga-PSMA-11 PET/CT and 68Ga-PSMA-11 PET/MRI in patients …
the diagnostic efficacy of 68Ga-PSMA-11 PET/CT and 68Ga-PSMA-11 PET/MRI in patients …
The Evolving Role of 18F-FDG PET/CT in Diagnosis and Prognosis Prediction in Progressive Prostate Cancer
Positron emission tomography/computed tomography (PET/CT) is widely used in prostate
cancer to evaluate the localized tumor burden and detect symptomatic metastatic lesions …
cancer to evaluate the localized tumor burden and detect symptomatic metastatic lesions …
68Ga-RM2 PET–MRI versus MRI alone for evaluation of patients with biochemical recurrence of prostate cancer: a single-centre, single-arm, phase 2/3 imaging trial
H Duan, F Moradi, GA Davidzon, T Liang… - The Lancet …, 2024 - thelancet.com
Summary Background National Comprehensive Cancer Network guidelines include
prostate-specific membrane antigen (PSMA)-targeted PET for detection of biochemical …
prostate-specific membrane antigen (PSMA)-targeted PET for detection of biochemical …
Detection rate of gastrin-releasing peptide receptor (GRPr) targeted tracers for positron emission tomography (PET) imaging in primary prostate cancer: a systematic …
G Belge Bilgin, C Bilgin, A Orscelik, BJ Burkett… - Annals of Nuclear …, 2024 - Springer
The gastrin-releasing peptide receptor (GRPr) has gained recognition as a promising target
for both diagnostic and therapeutic applications in a variety of human cancers. This study …
for both diagnostic and therapeutic applications in a variety of human cancers. This study …
[HTML][HTML] Spatial Genomics Identifies Heat Shock Proteins as Key Molecular Changes Associated to Adipose Periprostatic Space Invasion in Prostate Cancer
O Cussenot, L Poupel, C Mousset, J Lavergne… - Cancers, 2024 - mdpi.com
Purpose: To identify molecular changes during PCa invasion of adipose space using Spatial
Transcriptomic Profiling of PCa cells. Methods: This study was performed on paired …
Transcriptomic Profiling of PCa cells. Methods: This study was performed on paired …
Prospective Comparison of 68Ga-NeoB and 68Ga-PSMA-R2 PET/MRI in Patients with Biochemically Recurrent Prostate Cancer
Prostate-specific membrane antigen (PSMA) and gastrin-releasing peptide receptors are
both overexpressed in prostate cancer (PC) but may provide complementary information …
both overexpressed in prostate cancer (PC) but may provide complementary information …
A risk model for patients with PSA-only recurrence (biochemical recurrence) based on PSA and PSMA PET/CT: An individual patient data meta-analysis
R von Eyben, DS Kapp, MA Hoffmann, C Soydal… - Cancers, 2022 - mdpi.com
Simple Summary We undertook an individual patient data meta-analysis of the overall
survival of 1216 patients with PSA-only recurrence of prostate cancer restaged with PSMA …
survival of 1216 patients with PSA-only recurrence of prostate cancer restaged with PSMA …
Clinical Tools for Optimizing Therapeutic Decision-Making in Prostate Cancer: A Five-Year Retrospective Analysis
SC Latcu, AA Cumpanas, V Barbos, VB Buciu, M Raica… - Life, 2024 - mdpi.com
The effective staging of prostate cancer is essential for optimizing treatment and predicting
outcomes. This study assessed the correlation between detailed preoperative diagnostic …
outcomes. This study assessed the correlation between detailed preoperative diagnostic …